Novo Nordisk (NVO) signs up to €1.165B deal with Nanexa for PharmaShell drug-delivery tech for obesity & diabetes peptides.

S&P Global’s flash PMI surveys indicated a further improvement in economic growth across the G4 advanced economies to the ...

Up to 10% of 1-share trades and 20% of dark pool trades trade through better-priced odd lots. Partial Fills Worsen the ...

SBIO should be treated as a speculative satellite holding; broader ETFs like XBI or IBB offer more balanced risk and maturity ...

NHP's ongoing divestiture of outpatient medical facilities and reinvestment into senior housing operating properties should ...

I can't find any debt to GDP level that reliably predicts default or high inflation for a country that borrows in its own ...

Euan Craik, global head of oil at Argus Media, discusses oil exports and other changes that made the U.S. the key global ...

Dutch Bros (BROS) rated Hold: strong unit economics, but slowing transactions and rich valuation. Read here for a detailed ...

Taiwan Semiconductor remains a buy as AI-driven growth lifts results and outlook, with attractive valuation despite 2nm, ...

In this monthly series, I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. This ...

Clorox looks more attractive as ERP issues fade; GOJO adds growth and guidance improves. Read here for a detailed investment ...

Sustainable Aware Advantage Large Cap Core Fund posted returns of 16.41% (Institutional shares) and 16.35% (Investor A shares ...